MoonLake regains momentum after the FDA Type B meeting allows BLA submission for sonelokimab in HS without additional trials.
Amendments to key IMO treaties include reporting lost containers and mandatory training on preventing harassment and bullying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback